Moderna woos trial vet Melanie Ivarsson to the senior R&D team; Ex-Roche CMO Sandra Horning joins Gilead board
Moderna was founded 10 years ago and early on grew into a unicorn with grand ambitions for a broad preclinical effort in messenger RNA. Now that it has shifted a large number of those candidates — along with some blockbuster expectations — into clinical development, the biotech has recruited a development chief. And they’ve turned to an experienced hand from Big Pharma to get the job done.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.